The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.

Andrea  Cercek

Consulting or Advisory Role - Bayer; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen

Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen

Jean-Baptiste  Bachet

Honoraria - Amgen; AstraZeneca; Bayer; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Sanofi; SERVIER; Viatris

Consulting or Advisory Role - AC BioScience; Acobiom; Amgen; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Incyte; Merck Serono; MSD; Pierre Fabre; Servier

Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Servier

Jaume  Capdevila

Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi

Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi

Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Eisai; Ipsen; Pfizer

Naureen  Starling

Honoraria - Amgen; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER

Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; MSD; MSD Oncology; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer; SERVIER

Research Funding - AstraZeneca (Inst); BMS (Inst); Guardant Health (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst)

Travel, Accommodations, Expenses - Guardant Health; MSD Oncology

(OPTIONAL) Uncompensated Relationships - Guardant Health

Eric Xueyu  Chen

Honoraria - AstraZeneca Canada; Bayer; Eisai; Ipsen

Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada

Maria  Di Bartolomeo

Honoraria - BMSi; Lilly; MSD Oncology; SERVIER

Consulting or Advisory Role - Lilly; MSD Oncology

Research Funding - Lilly (Inst)

Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca

Takayuki  Yoshino

Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical

Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)

Gordana  Vlahovic

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Eleftherios  Zografos

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Sean  O'Donnell

Employment - GlaxoSmithKline

Stock and Other Ownership Interests  - GlaxoSmithKline

Other Relationship - My spouse is a federal government employee (I)

Zsolt  Szijgyarto

Employment - AstraZeneca; GlaxoSmithKline

Stock and Other Ownership Interests  - AstraZeneca; GlaxoSmithKline

Volker  Heinemann

Honoraria - Amgen; AstraZeneca; Merck; MSD; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; SERVIER

Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck; MSD; MSD Oncology; Nordic Bioscience; Novartis; Oncosil; Pierre Fabre; Roche; Servier/Pfizer; TERUMO

Research Funding - Amgen (Inst); Merck (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Merck